Wednesday, July 8, 2026

Drug profile · INN

flucytosine

flucytosine (FLUCYTOSINE) is a thymidylate synthase inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — flucytosine
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

flucytosine (FLUCYTOSINE) is a thymidylate synthase inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN flucytosine
Brand FLUCYTOSINE
Mechanism Thymidylate synthase inhibitor
Target Thymidylate synthase
Route ORAL
Formulation CAPSULE

Mechanism of action

Thymidylate synthase inhibitor

Primary target: Thymidylate synthase

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. floxuridine Thymidylate synthase inhibitor
  2. pyrimethamine Dihydrofolate reductase inhibitor
  3. raltitrexed Thymidylate synthase inhibitor

Frequently asked questions

What is flucytosine?

flucytosine (FLUCYTOSINE) is a thymidylate synthase inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for flucytosine?

FLUCYTOSINE is a marketed brand name for flucytosine. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of flucytosine?

flucytosine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.